Saluda Medical has announced that its data will be presented at the upcoming North American Neuromodulation Society (NANS) annual meeting (18–21 January, Las Vegas, USA).
With the company’s three-year EVOKE study having demonstrated superior pain relief in its closed-loop arm versus its open-loop arm, a late-breaking presentation of data at NANS 2024 will demonstrate that SmartLoop therapy is associated with “significantly better adherence” to prescribed electrical dose as compared to open-loop stimulation.
This evidence “may usher in a new era of objective therapy measures” that enable improved long-term clinical outcomes for spinal cord stimulation (SCS), as per a Saluda press release. Precise neural dosing with SmartLoop is possible through real-time measurements of evoked compound action potentials (ECAPs), which are direct measures of the nerve fibres’ response to stimulation.
In addition to this late-breaking presentation, the 13 posters and presentations set to be presented at NANS will include additional data on long-term clinical SCS results, and neural monitoring to optimise the long-term efficacy of SCS therapy as well as identify responders from non-responders during the SCS trial evaluation phase.
According to Saluda, NANS 2024 podium presentations relating to the EVOKE randomised controlled trial—as well as the Avalon and DR studies—include:
- “Late-breaking session: three-year durable outcomes and dose response with ECAP closed-loop SCS for treatment of chronic pain”—Nagy Mekhail (Cleveland Clinic, Cleveland, USA)
- “Attaining maximal analgesic effect with objective neurophysiological measurements”—Robert Levy (Marcus Neuroscience Institute, Boca Raton, USA)
- “Increasing treatment response after two years of open-loop SCS therapy: crossover patient insights”—Jason Pope (Evolve Restorative Center, Santa Rosa, USA)
- “Big ECAP data: a novel objective neural panel for SCS therapy optimisation”—Ajay Antony (The Orthopaedic Institute, Gainesville, USA).
“Saluda Medical has been on a journey to transform neuromodulation and solve large unmet clinical and health economic needs. The evidence presented at NANS demonstrates SmartLoop’s capability to provide long-term superior outcomes for patients as well as advance SCS therapy efficiencies for clinical practices,” said Jim Schuermann, president and chief executive officer of Saluda.
